2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

3219 ACOT9 silencing renders T-cell acute lymphoblastic leukemia dependent on the succinyl-CoA synthetase complex

Stefan Bjelosevic, PhD, Nicholas K O'Neill, PhD2, Keene L Abbott3, Gabriela Alexe, PhD4, Shadwa Bayoumi5, Lucy Merickel6, Haider Inam7, Lindsey Elizabeth Montefiori, PhD8, Petri Polonen, PhD9, Yiming Wu10, Amanda Thuy Van Vo11, Ryan Elbashir12, Francisca Vazquez, PhD13, Charles G. Mullighan, MBBS (Hons), MSc, MD14, Matthew Vander Heiden, MD, PhD15, Pere Puigserver16, Kimberly Stegmaier, MD17
1 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
8 St Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St Jude Children's Research Hospital, Memphis, Tennessee, United States
11 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Koch Institute For Integrative Cancer Research at MIT, Cambridge, Massachusetts, United States, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
13 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
14 St Jude Children's Research Hospital, Memphis, Tennessee, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Koch Institute For Integrative Cancer Research at MIT, Cambridge, Massachusetts, United States, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
17 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
Genome-wide CRISPR-Cas screens through the Cancer Dependency Map (DepMap) have yielded disease- and context-specific dependencies in human cancers that are now tractable targets, exemplified by the Werner syndrome helicase WRN as a dependency in microsatellite instability-high (MSI-H) cancers. Such discoveries require screening at scale across models which capture the genetic heterogeneity of a malignancy. In the first stage of the Pediatric Cancer Dependencies Accelerator (PedDep), we addressed T-cell acute lymphoblastic leukemia (T-ALL), a disease entity historically underrepresented in DepMap. We optimized Cas screening parameters and performed genome-wide dependency screens with deep molecular characterization of 20 T-ALL cell lines, expanding available models in DepMap by over six-fold and including previously unrepresented genetic subtypes such as TLX3, NKX2-5, ETP-like and high-risk STAG2::LMO2.

Two-class dependency analyses against all other DepMap models identified SUCLA2 and SUCLG1, encoding two subunits of the heterodimeric mitochondrial succinyl-CoA synthetase (SCS) complex, as strongly enriched dependencies in T-ALL. SCS interconverts succinyl-CoA and succinate in the tricarboxylic (TCA) cycle and is comprised of an invariant alpha subunit (SUCLG1) and a nucleotide-specifying beta subunit; either the ATP-specific SUCLA2 or the GTP-specific SUCLG2. Deletion of SUCLA2 or SUCLG1 (hereafter SCS loss) ablated proliferation across genetically diverse T-ALL subtypes in culture medium designed to mimic human plasma, whereas both were dispensable in donor-derived CD34+ hematopoietic stem and progenitor cells (HSPCs). Consistent with DepMap predictions, SUCLG2 was dispensable in T-ALL.

Expression-dependency correlation analyses revealed that low expression of the acyl-CoA thioesterase ACOT9 is the primary determinant of response to SCS loss. ACOTs are a conserved family of hydrolases that differ in acyl-CoA substrate preference and subcellular localization; ACOT9 is a mitochondrial enzyme that hydrolyses acyl-CoAs into free acids and coenzyme A. Via analysis of CpG methylation and PRC2-mediated H3K27me3 deposition, we discovered that ACOT9 is recurrently silenced in T-ALL relative to normal tissues, including in a large pediatric cohort, and in subtypes of Hodgkin lymphoma, diffuse large B-cell lymphoma, and small-cell lung cancer. ACOT9 deletion potently sensitized otherwise-resistant models to SCS loss, whereas enforced ACOT9 expression completely reversed SCS dependency in T-ALL. Importantly, rescue required thioesterase activity within the mitochondrion: ACOT9 lacking its mitochondrial localization sequence (MLS) failed to rescue SCS loss, as did expression of the peroxisomal-localized ACOT4, the primary succinyl-CoA thioesterase. Accordingly, MLS-targeted ACOT4 rescued completely, revealing mitochondrial succinyl-CoA hydrolysis as the determinant of sensitivity.

In inborn errors of metabolism, pathogenic SUCLA2 or SUCLG1 variants cause accumulation of succinyl-CoA, which non-enzymatically succinylates lysine residues to alter protein stability and function. Hypersuccinylation is a proposed driver of the disease's molecular features such as mtDNA depletion and impaired respiratory capacity. Consistent with this, SCS-deleted T-ALL cells showed global protein hypersuccinylation. To define the downstream consequences of SCS loss, we performed targeted metabolomic profiling. This analysis revealed accumulation of α-ketoglutarate and glutamate, with concomitant depletion of fumarate, malate, and aspartate. Malate depletion alongside aspartate, rather than aspartate alone, suggests increased aspartate consumption by transamination (driven by α-ketoglutarate accumulation) rather than reduced synthesis. Consistent with aspartate's role as a nucleotide precursor, nucleotide pools were reduced and we observed induction of replicative stress marked by Chk1/Chk2 phosphorylation. Strikingly, enforced ACOT9 expression reversed the proteomic, metabolomic, and replicative stress phenotypes of SCS loss, indicating that normalization of mitochondrial acyl-CoA pools is sufficient to rescue the consequences of SCS deletion.

Collectively, we describe the SCS complex as a selective vulnerability in T-ALL that spares normal hematopoiesis and define a robust biomarker of response. Recurrent silencing of ACOT9 across lymphoid and solid tumors suggests SCS inhibition may be a therapeutic avenue well beyond T-ALL.
Stefan Bjelosevic, PhD: Ramsay Healthcare Ltd - Divested equity in a private or publicly-traded company in the past 24 months